CLEVER CULTURE SYSTEMS LIMITED - Announcements

2.86%

3.6¢

Market Cap $65.33M

Healthcare Biotechnology

Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based... Clever Culture Systems Limited, formerly LBT Innovations Limited, is an Australia-based company that provides intelligent automation solutions to microbiology laboratories. The Company has developed a technology, the Automated Plate Assessment System (APAS Independence), using artificial intelligence (AI) and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology is a United States FDA-cleared AI technology for automated culture plate reading. The product is being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is the exclusive distributor of the APAS Independence to clinical customers in the United States and selected countries in Europe.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/25	549.85KB	Share
CC5	Instrument Sale to Novo Nordisk for Group Evaluation	PRICE SENSITIVE	14/07/25	163.11KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/25	452.15KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/25	1014.34KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	448KB	Share
CC5	Additional Four Instruments Ordered by AstraZeneca	PRICE SENSITIVE	05/12/24	162.62KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/24	391.36KB	Share
CC5	LBT Announce Bristol Myers Squibb Purchase APAS Independence	PRICE SENSITIVE	22/10/24	119.59KB	Share
CC5	Appendix 4E	PRICE SENSITIVE	29/08/24	123.77KB	Share
CC5	ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M	PRICE SENSITIVE	07/08/24	125.99KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/24	396.98KB	Share
CC5	Response to ASX Price Query	PRICE SENSITIVE	14/06/24	283.04KB	Share
CC5	Lift of Pause in Trading	PRICE SENSITIVE	13/06/24	85.41KB	Share
CC5	Pause in Trading	PRICE SENSITIVE	13/06/24	114.48KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	330.74KB	Share
CC5	APAS PHARMAQC SALE TO NOVACINA	PRICE SENSITIVE	29/04/24	125.89KB	Share
CC5	APAS PharmaQC Commercially Ready - Performance Finalised	PRICE SENSITIVE	13/03/24	164.33KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/24	762.57KB	Share
CC5	Delivery Completes First Sale of APAS PharmaQC	PRICE SENSITIVE	22/02/24	116.03KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	22/01/24	298.61KB	Share
CC5	Placement Completes Financial Restructure	PRICE SENSITIVE	20/11/23	132.13KB	Share
CC5	Renounceable Rights Issue Results	PRICE SENSITIVE	15/11/23	119.95KB	Share
CC5	$1.7M SA Government Loan Restructure	PRICE SENSITIVE	06/11/23	148.64KB	Share
CC5	Entitlement Offer Underwriting Increased to $3.6M	PRICE SENSITIVE	27/10/23	81.08KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/23	385.09KB	Share
CC5	Prospectus	PRICE SENSITIVE	13/10/23	788.16KB	Share
CC5	$4.5 million Entitlement Offer	PRICE SENSITIVE	13/10/23	148.04KB	Share
CC5	Full Repayment of $1.38M Share Placement Facility	PRICE SENSITIVE	13/10/23	114.6KB	Share
CC5	Preliminary Annual Financial Report & Appendix 4E	PRICE SENSITIVE	31/08/23	899.3KB	Share
CC5	Non-Cash Impairment of Intangible Assets	PRICE SENSITIVE	04/08/23	116.2KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	351.93KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	365.77KB	Share
CC5	Placement Supports APAS Pharma & EU Expansion	PRICE SENSITIVE	20/03/23	174.43KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.17MB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/01/23	463.53KB	Share
CC5	AstraZeneca Partners LBT for APAS Pharma Development	PRICE SENSITIVE	09/01/23	117.2KB	Share
CC5	LBT Strengthens APAS Pharma Development	PRICE SENSITIVE	20/12/22	110.44KB	Share
CC5	CCS Appoint Thermo Fisher as Exclusive European Distributor	PRICE SENSITIVE	19/12/22	115.88KB	Share
CC5	Non-renounceable Rights Issue Results	PRICE SENSITIVE	28/11/22	114.71KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	456.94KB	Share
CC5	Rights Issue Prospectus	PRICE SENSITIVE	25/10/22	630.34KB	Share
CC5	Non-Renounceable Rights Issue	PRICE SENSITIVE	25/10/22	198.85KB	Share
CC5	$1.5M Funding Awarded for New APAS Instrument	PRICE SENSITIVE	24/10/22	207.89KB	Share
CC5	Appendix 4E	PRICE SENSITIVE	29/08/22	126.33KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	284.83KB	Share
CC5	Direct Sale of APAS Independence in United States	PRICE SENSITIVE	03/05/22	174.44KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	451.86KB	Share
CC5	Purchase Order for Multiple APAS Instruments	PRICE SENSITIVE	16/03/22	154.35KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	948.1KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	357.01KB	Share
CC5	LBT Investor Call to discuss CCS Acquisition	PRICE SENSITIVE	11/01/22	995.92KB	Share
CC5	LBT Completes CCS Acquisition	PRICE SENSITIVE	04/01/22	131.87KB	Share
CC5	LBT to Obtain Full Ownership of CCS Joint Venture	PRICE SENSITIVE	29/12/21	146.74KB	Share
CC5	Market Update - Sales Pipeline and Evaluations	PRICE SENSITIVE	08/12/21	163.72KB	Share
CC5	US FDA 510(k) Clearance for MRSA Analysis Module	PRICE SENSITIVE	29/10/21	335.82KB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	444.4KB	Share
CC5	CCS Appoints Thermo Fisher as Exclusive US APAS Distributor	PRICE SENSITIVE	27/09/21	185.99KB	Share
CC5	Appendix 4E and Annual Financial Statements	PRICE SENSITIVE	26/08/21	1.49MB	Share
CC5	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/21	335.85KB	Share
CC5	APAS Independence Sales to Health Services Laboratory, UK	PRICE SENSITIVE	18/05/21	128.66KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/21	368.76KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	19/02/21	822.04KB	Share
CC5	Market Update - Board Renewal Process	PRICE SENSITIVE	01/02/21	123.51KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/01/21	348.28KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/20	352.13KB	Share
CC5	$0.75m Funding Awarded for APAS-AMR Analysis Module	PRICE SENSITIVE	03/09/20	584.65KB	Share
CC5	Appendix 4E	PRICE SENSITIVE	27/08/20	122.55KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	378.29KB	Share
CC5	Oneservice Appointed Managed Service Provider for APAS	PRICE SENSITIVE	13/07/20	145.38KB	Share
CC5	Proposed issue of Securities - LBT	PRICE SENSITIVE	09/07/20	34.63KB	Share
CC5	$8M PRIVATE PLACEMENT & LAUNCH OF SPP	PRICE SENSITIVE	09/07/20	1.56MB	Share
CC5	Trading Halt	PRICE SENSITIVE	07/07/20	338.52KB	Share
CC5	Pause in Trading	PRICE SENSITIVE	07/07/20	115.04KB	Share
CC5	LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTICS COMPANY	PRICE SENSITIVE	07/07/20	316KB	Share
CC5	Results of Evaluation of APAS Independence by Johns Hopkins	PRICE SENSITIVE	30/06/20	451.88KB	Share
CC5	First Sale of APAS Independence in United States	PRICE SENSITIVE	09/06/20	135.7KB	Share
CC5	Update on MRSA Analysis Module US FDA Submission	PRICE SENSITIVE	04/06/20	164.71KB	Share
CC5	$1.5M Draw Down on South Australian Government Loan	PRICE SENSITIVE	26/05/20	145.68KB	Share
CC5	South Australian Government Agree to Extend Loan Facility	PRICE SENSITIVE	08/05/20	131.29KB	Share
CC5	Presentation at NWR Virtual Small Cap Conference	PRICE SENSITIVE	30/04/20	1.42MB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/20	343.93KB	Share
CC5	US FDA 510(k) Submission for MRSA Analysis Module	PRICE SENSITIVE	30/03/20	136.56KB	Share
CC5	VRE Analysis Module - Clinical Study Commenced	PRICE SENSITIVE	19/03/20	135.38KB	Share
CC5	Johns Hopkins Hosp to Present Study Data APAS Independence	PRICE SENSITIVE	12/03/20	155.67KB	Share
CC5	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	755.69KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/20	323.01KB	Share
CC5	LBT Receives $1.1 Million R&D Tax Incentive	PRICE SENSITIVE	22/01/20	101.73KB	Share
CC5	Presentation at Biotech Showcase Investor Conference	PRICE SENSITIVE	14/01/20	1.52MB	Share
CC5	CEO Presentation - AGM 2019	PRICE SENSITIVE	27/11/19	1.42MB	Share
CC5	Chairman's Address to Shareholders	PRICE SENSITIVE	27/11/19	109.92KB	Share
CC5	Non-Executive Director Retirement	PRICE SENSITIVE	30/10/19	128.69KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	25/10/19	298.57KB	Share
CC5	First European Sale of APAS Independence	PRICE SENSITIVE	21/10/19	145.61KB	Share
CC5	LBT Presents at ExchangeSA Conference in Adelaide	PRICE SENSITIVE	26/09/19	2.31MB	Share
CC5	MRSA Analysis Module CE Mark Registration	PRICE SENSITIVE	25/09/19	133.87KB	Share
CC5	European Union Regulatory Certification & MRSA Study Results	PRICE SENSITIVE	16/09/19	145.9KB	Share
CC5	Appendix 4E Full Year Report	PRICE SENSITIVE	29/08/19	141.14KB	Share
CC5	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/19	291.44KB	Share
CC5	Update on Distributor Appointments	PRICE SENSITIVE	22/07/19	140.02KB	Share
CC5	South Australian Government Loan $1.5M Drawdown	PRICE SENSITIVE	27/06/19	131.69KB	Share

CC5 Quarterly Activities/Appendix 4C Cash Flow Report
29/07/25	PRICE SENSITIVE	549.85KB	Share
CC5 Instrument Sale to Novo Nordisk for Group Evaluation
14/07/25	PRICE SENSITIVE	163.11KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
28/04/25	PRICE SENSITIVE	452.15KB	Share
CC5 Half Yearly Report and Accounts
21/02/25	PRICE SENSITIVE	1014.34KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	448KB	Share
CC5 Additional Four Instruments Ordered by AstraZeneca
05/12/24	PRICE SENSITIVE	162.62KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
28/10/24	PRICE SENSITIVE	391.36KB	Share
CC5 LBT Announce Bristol Myers Squibb Purchase APAS Independence
22/10/24	PRICE SENSITIVE	119.59KB	Share
CC5 Appendix 4E
29/08/24	PRICE SENSITIVE	123.77KB	Share
CC5 ASTRAZENECA SALE & SERVICE CONTRACT UP TO A$4.1M
07/08/24	PRICE SENSITIVE	125.99KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
25/07/24	PRICE SENSITIVE	396.98KB	Share
CC5 Response to ASX Price Query
14/06/24	PRICE SENSITIVE	283.04KB	Share
CC5 Lift of Pause in Trading
13/06/24	PRICE SENSITIVE	85.41KB	Share
CC5 Pause in Trading
13/06/24	PRICE SENSITIVE	114.48KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	330.74KB	Share
CC5 APAS PHARMAQC SALE TO NOVACINA
29/04/24	PRICE SENSITIVE	125.89KB	Share
CC5 APAS PharmaQC Commercially Ready - Performance Finalised
13/03/24	PRICE SENSITIVE	164.33KB	Share
CC5 Half Yearly Report and Accounts
23/02/24	PRICE SENSITIVE	762.57KB	Share
CC5 Delivery Completes First Sale of APAS PharmaQC
22/02/24	PRICE SENSITIVE	116.03KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
22/01/24	PRICE SENSITIVE	298.61KB	Share
CC5 Placement Completes Financial Restructure
20/11/23	PRICE SENSITIVE	132.13KB	Share
CC5 Renounceable Rights Issue Results
15/11/23	PRICE SENSITIVE	119.95KB	Share
CC5 $1.7M SA Government Loan Restructure
06/11/23	PRICE SENSITIVE	148.64KB	Share
CC5 Entitlement Offer Underwriting Increased to $3.6M
27/10/23	PRICE SENSITIVE	81.08KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
26/10/23	PRICE SENSITIVE	385.09KB	Share
CC5 Prospectus
13/10/23	PRICE SENSITIVE	788.16KB	Share
CC5 $4.5 million Entitlement Offer
13/10/23	PRICE SENSITIVE	148.04KB	Share
CC5 Full Repayment of $1.38M Share Placement Facility
13/10/23	PRICE SENSITIVE	114.6KB	Share
CC5 Preliminary Annual Financial Report & Appendix 4E
31/08/23	PRICE SENSITIVE	899.3KB	Share
CC5 Non-Cash Impairment of Intangible Assets
04/08/23	PRICE SENSITIVE	116.2KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	351.93KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	365.77KB	Share
CC5 Placement Supports APAS Pharma & EU Expansion
20/03/23	PRICE SENSITIVE	174.43KB	Share
CC5 Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.17MB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
23/01/23	PRICE SENSITIVE	463.53KB	Share
CC5 AstraZeneca Partners LBT for APAS Pharma Development
09/01/23	PRICE SENSITIVE	117.2KB	Share
CC5 LBT Strengthens APAS Pharma Development
20/12/22	PRICE SENSITIVE	110.44KB	Share
CC5 CCS Appoint Thermo Fisher as Exclusive European Distributor
19/12/22	PRICE SENSITIVE	115.88KB	Share
CC5 Non-renounceable Rights Issue Results
28/11/22	PRICE SENSITIVE	114.71KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	456.94KB	Share
CC5 Rights Issue Prospectus
25/10/22	PRICE SENSITIVE	630.34KB	Share
CC5 Non-Renounceable Rights Issue
25/10/22	PRICE SENSITIVE	198.85KB	Share
CC5 $1.5M Funding Awarded for New APAS Instrument
24/10/22	PRICE SENSITIVE	207.89KB	Share
CC5 Appendix 4E
29/08/22	PRICE SENSITIVE	126.33KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	284.83KB	Share
CC5 Direct Sale of APAS Independence in United States
03/05/22	PRICE SENSITIVE	174.44KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	451.86KB	Share
CC5 Purchase Order for Multiple APAS Instruments
16/03/22	PRICE SENSITIVE	154.35KB	Share
CC5 Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	948.1KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	357.01KB	Share
CC5 LBT Investor Call to discuss CCS Acquisition
11/01/22	PRICE SENSITIVE	995.92KB	Share
CC5 LBT Completes CCS Acquisition
04/01/22	PRICE SENSITIVE	131.87KB	Share
CC5 LBT to Obtain Full Ownership of CCS Joint Venture
29/12/21	PRICE SENSITIVE	146.74KB	Share
CC5 Market Update - Sales Pipeline and Evaluations
08/12/21	PRICE SENSITIVE	163.72KB	Share
CC5 US FDA 510(k) Clearance for MRSA Analysis Module
29/10/21	PRICE SENSITIVE	335.82KB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	444.4KB	Share
CC5 CCS Appoints Thermo Fisher as Exclusive US APAS Distributor
27/09/21	PRICE SENSITIVE	185.99KB	Share
CC5 Appendix 4E and Annual Financial Statements
26/08/21	PRICE SENSITIVE	1.49MB	Share
CC5 Quarterly Activities/Appendix 4C Cash Flow Report
28/07/21	PRICE SENSITIVE	335.85KB	Share
CC5 APAS Independence Sales to Health Services Laboratory, UK
18/05/21	PRICE SENSITIVE	128.66KB	Share
CC5 Appendix 4C - quarterly
29/04/21	PRICE SENSITIVE	368.76KB	Share
CC5 Half Yearly Report and Accounts
19/02/21	PRICE SENSITIVE	822.04KB	Share
CC5 Market Update - Board Renewal Process
01/02/21	PRICE SENSITIVE	123.51KB	Share
CC5 Appendix 4C - quarterly
29/01/21	PRICE SENSITIVE	348.28KB	Share
CC5 Appendix 4C - quarterly
27/10/20	PRICE SENSITIVE	352.13KB	Share
CC5 $0.75m Funding Awarded for APAS-AMR Analysis Module
03/09/20	PRICE SENSITIVE	584.65KB	Share
CC5 Appendix 4E
27/08/20	PRICE SENSITIVE	122.55KB	Share
CC5 Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	378.29KB	Share
CC5 Oneservice Appointed Managed Service Provider for APAS
13/07/20	PRICE SENSITIVE	145.38KB	Share
CC5 Proposed issue of Securities - LBT
09/07/20	PRICE SENSITIVE	34.63KB	Share
CC5 $8M PRIVATE PLACEMENT & LAUNCH OF SPP
09/07/20	PRICE SENSITIVE	1.56MB	Share
CC5 Trading Halt
07/07/20	PRICE SENSITIVE	338.52KB	Share
CC5 Pause in Trading
07/07/20	PRICE SENSITIVE	115.04KB	Share
CC5 LBT TEAMS WITH GLOBAL CLINICAL DIAGNOSTICS COMPANY
07/07/20	PRICE SENSITIVE	316KB	Share
CC5 Results of Evaluation of APAS Independence by Johns Hopkins
30/06/20	PRICE SENSITIVE	451.88KB	Share
CC5 First Sale of APAS Independence in United States
09/06/20	PRICE SENSITIVE	135.7KB	Share
CC5 Update on MRSA Analysis Module US FDA Submission
04/06/20	PRICE SENSITIVE	164.71KB	Share
CC5 $1.5M Draw Down on South Australian Government Loan
26/05/20	PRICE SENSITIVE	145.68KB	Share
CC5 South Australian Government Agree to Extend Loan Facility
08/05/20	PRICE SENSITIVE	131.29KB	Share
CC5 Presentation at NWR Virtual Small Cap Conference
30/04/20	PRICE SENSITIVE	1.42MB	Share
CC5 Appendix 4C - quarterly
28/04/20	PRICE SENSITIVE	343.93KB	Share
CC5 US FDA 510(k) Submission for MRSA Analysis Module
30/03/20	PRICE SENSITIVE	136.56KB	Share
CC5 VRE Analysis Module - Clinical Study Commenced
19/03/20	PRICE SENSITIVE	135.38KB	Share
CC5 Johns Hopkins Hosp to Present Study Data APAS Independence
12/03/20	PRICE SENSITIVE	155.67KB	Share
CC5 Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	755.69KB	Share
CC5 Appendix 4C - quarterly
30/01/20	PRICE SENSITIVE	323.01KB	Share
CC5 LBT Receives $1.1 Million R&D Tax Incentive
22/01/20	PRICE SENSITIVE	101.73KB	Share
CC5 Presentation at Biotech Showcase Investor Conference
14/01/20	PRICE SENSITIVE	1.52MB	Share
CC5 CEO Presentation - AGM 2019
27/11/19	PRICE SENSITIVE	1.42MB	Share
CC5 Chairman's Address to Shareholders
27/11/19	PRICE SENSITIVE	109.92KB	Share
CC5 Non-Executive Director Retirement
30/10/19	PRICE SENSITIVE	128.69KB	Share
CC5 Appendix 4C - quarterly
25/10/19	PRICE SENSITIVE	298.57KB	Share
CC5 First European Sale of APAS Independence
21/10/19	PRICE SENSITIVE	145.61KB	Share
CC5 LBT Presents at ExchangeSA Conference in Adelaide
26/09/19	PRICE SENSITIVE	2.31MB	Share
CC5 MRSA Analysis Module CE Mark Registration
25/09/19	PRICE SENSITIVE	133.87KB	Share
CC5 European Union Regulatory Certification & MRSA Study Results
16/09/19	PRICE SENSITIVE	145.9KB	Share
CC5 Appendix 4E Full Year Report
29/08/19	PRICE SENSITIVE	141.14KB	Share
CC5 Appendix 4C - quarterly
29/07/19	PRICE SENSITIVE	291.44KB	Share
CC5 Update on Distributor Appointments
22/07/19	PRICE SENSITIVE	140.02KB	Share
CC5 South Australian Government Loan $1.5M Drawdown
27/06/19	PRICE SENSITIVE	131.69KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.6¢		Change 0.001(2.86%)		Mkt cap ! $65.33M

Open	High	Low	Value	Volume
3.5¢	3.6¢	3.5¢	$18.02K	513.3K

Buyers (Bids)

No.	Vol.	Price($)
7	991682	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.6¢	1072927	5

View Market Depth

No.	Vol.	Price($)
7	991682	0.034
6	971865	0.033
4	504275	0.032
1	32258	0.031
4	618150	0.030

Price($)	Vol.	No.
0.036	1072927	5
0.037	1353817	1
0.039	1128436	4
0.040	3000000	2
0.041	300000	1

Last trade - 15.55pm 21/08/2025 (20 minute delay)


Last 3.6¢		Change 0.001 ( 2.86 %)
Open	High	Low	Volume
3.5¢	3.6¢	3.5¢	84104
Last updated 15.55pm 21/08/2025 ?

CC5 (ASX) Chart

CLEVER CULTURE SYSTEMS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories